<DOC>
	<DOCNO>NCT00875030</DOCNO>
	<brief_summary>The primary objective study determine bioequivalence 50 mg ( 2x25 mg ) Artesunate Sachet ( Pfizer ) versus 50 mg ( 1x50 mg ) tablet , Arsuamoon® ( Guilin China ) World Health Organization Reference standard artesunate The secondary objective ass safety Artesunate Sachet ( Pfizer ) Arsuamoon® tablet ( Guilin China ) .</brief_summary>
	<brief_title>A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets ( Pfizer ) Versus Single-Dose Administration Of Arsuamoon® Tablets ( Guilin-China ) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 18 30 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . An informed consent document sign date subject legally acceptable representative . Any condition possibly affect drug absorption . A positive urine drug screen . Have know history hypersensitivity , allergy ( except untreated , asymptomatic , seasonal allergy time dose ) , severe adverse drug reaction , intolerance artesunate derivative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Bioequivalence study-artesunate sachets-arsuamoon tablet</keyword>
</DOC>